CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 860 enrolled
Drug / intervention
Piroxicam 40 mg +1 moredrug
Likely dose
Piroxicam 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03614494
NCT03614494Phase 3Completed
CompareCT.gov

Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception: Randomised Controlled Trial

Dr. Hang Wun Raymond Li·interventional·Posted Aug 3, 2018·Updated May 6, 2024

In Brief

A Phase 3 clinical trial evaluating Piroxicam 40 mg and Levonorgestrel 1.5mg for Emergency Contraception. Completed, enrolled 860 participants across 2 sites.

Detailed Summary

This is a randomised controlled trial aimed at comparing the efficacy of levonorgestrel (LNG) co-administered with piroxicam or placebo for oral emergency contraception (EC). Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a pain-killer in inflammatory conditions. Efficacy will be measured as the percentage of pregnancies prevented.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEmergency Contraception
CountriesHong Kong
CollaboratorsThe Family Planning Association of Hong Kong

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedAug 3, 2018
Enrollment StartAug 20, 2018
Primary CompletionOct 5, 2022
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 7.9 years ago

Interventions

Piroxicam 40 mgdrug

Additional co-treatment

Levonorgestrel 1.5mgdrug

Standard treatment